Recent Finacing
Recent Raise
Ascidian develops RNA exon editors that replace multiple mutated exons without DNA modification or exogenous enzymes, enabling treatment of large, highly variable genes; lead ABCA4 program targets Stargardt disease.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Ascidian Therapeutics.
